MDCX Medicus Pharma Ltd. Common Stock
USHealthcareAs of 2026-07-09 09:30
Why MDCX matters now
Medicus Pharma Ltd. Common Stock (MDCX) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.43 with -0.26% on the session and $9.4M in market capitalization; recent performance reads 1-month +64.57% and YTD -70.10%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-6.6M, and EPS of $-0.22. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -232.1%.
The latest indexable market news headline is "Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Ashton William filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
10.19
P/S
0.00
EV/EBITDA
-0.10
DCF Value
$0.08
FCF Yield
-232.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-4086.3%
ROA
-497.3%
ROIC
-2193.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-6.6M | $-0.22 |
| Q4 2025 | $0.00 | $-8.2M | $-0.43 |
| FY 2025 | $0.00 | $-25.4M | $-1.96 |
| Q3 2025 | $0.00 | $-16.0M | $-1.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
-0.46
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.